Literature DB >> 24080150

Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.

Charles E Mahan1, Maxine D Fisher, Roger M Mills, Larry E Fields, Judith J Stephenson, An-Chen Fu, Alex C Spyropoulos.   

Abstract

INTRODUCTION: Medically ill, hospitalized patients are at increased risk for venous thromboembolism (VTE) after discharge. This study aimed to examine thromboprophylaxis patterns, risk factors, and post-discharge outcomes.
METHODS: This was a retrospective claims analysis involving administrative claims data and in-patient data abstracted from a sample of hospital charts. Patients aged ≥ 40 years hospitalized for ≥ 2 days for nonsurgical reasons between 2005 and 2009 were included. Hospital chart data were abstracted for a random sample of patients without evidence of anticoagulant use at 30 days post-discharge. The combined data determined whether in-patient thromboprophylaxis (anticoagulant or mechanical prophylaxis) reduces risk of VTE at 90 days post-discharge. Hazard ratios (HR) and odds ratios (OR) were calculated using Cox proportional hazard models and logistic regression.
RESULTS: Of 141,628 patients in the claims analysis, 3.9% received anticoagulants (3.6% warfarin). VTE, rehospitalization, and mortality rates were 1.9%, 17.2%, and 6.2%, respectively. The strongest predictors of post-discharge VTE were history of VTE (HR=4.0, 95% confidence interval [CI]: 3.3-4.8), and rehospitalization (HR=3.9, 95% CI: 3.6-4.3). Of 504 medical charts, 209 (41.5%) reported in-patient thromboprophylaxis. There was no statistically significant difference in post-discharge VTE rates between patients who did and did not receive in-patient thromboprophylaxis. All-cause mortality was greater among patients without use of VTE prophylaxis.
CONCLUSION: Utilization rates of in-hospital and post-discharge VTE prophylaxis were low. In-hospital VTE prophylaxis did not reduce the risk of post-discharge VTE in the absence of post-discharge anticoagulation. Combined in-patient and post-discharge thromboprophylaxis lowered the odds of short-term, all-cause post-discharge mortality.
© 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CI; DCI; DVT; Deyo-Charlson Comorbidity Index; HIRD; HR; HealthCore Integrated Research Database; ICD-9-CM; International Classification of Diseases, Ninth Revision, Clinical Modification; LMWH; Medical patients; Mortality; OR; PE; Risk factors; SD; Thromboprophylaxis; VTE; Venous thromboembolism; confidence interval; deep vein thrombosis; hazard ratio; low-molecular-weight heparin; odds ratio; pulmonary embolism; standard deviation; venous thromboembolism

Mesh:

Substances:

Year:  2013        PMID: 24080150     DOI: 10.1016/j.thromres.2013.08.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?

Authors:  Franco Piovella; Diana Irina Iosub
Journal:  Intern Emerg Med       Date:  2018-09-27       Impact factor: 3.397

Review 2.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.

Authors:  Walter Ageno
Journal:  Intern Emerg Med       Date:  2017-08-14       Impact factor: 3.397

Review 3.  Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.

Authors:  Kayla M Miller; Michael J Brenner
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

4.  Prophylaxis of venous thromboembolism in Internal Medicine Units: the RAMs issue.

Authors:  Antonella Tufano; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2018-03-14       Impact factor: 3.397

Review 5.  COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Authors:  Xiaojing Chen; Chengyuan Yu; Haijiao Jing; Chunxu Wang; Xinyi Zhao; Jinming Zhang; Shuoqi Zhang; Huan Liu; Rujuan Xie; Jialan Shi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 6.  Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Aaron Y L Liew; Siavash Piran; John W Eikelboom; James D Douketis
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

Review 7.  Inflammatory bowel disease and thromboembolism.

Authors:  Petros Zezos; Georgios Kouklakis; Fred Saibil
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

9.  Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment.

Authors:  Andrea J Darzi; Samer G Karam; Frederick A Spencer; Alex C Spyropoulos; Lawrence Mbuagbaw; Scott C Woller; Neil A Zakai; Michael B Streiff; Michael K Gould; Mary Cushman; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Elie A Akl; Alfonso Iorio; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-06-23

10.  Analysis of risk factors for venous thromboembolism in patients after thoracic surgery: A clinical study of 167 cases.

Authors:  Wang Fei; Zhang Jian; Gao Zhi; Wang Rong; Li Jianxin; Gu Yongquan; Wang Weiping
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-01-09       Impact factor: 0.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.